Millipore and JPT Peptide Technologies (JPT), a wholly-owned subsidiary of Berlin-based Jerini, have announced a distribution and marketing agreement
This relationship gives Millipore worldwide, non-exclusive distribution rights for JPT's line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases and proteases.
This includes JPT's line of enzyme substrate sets and microarrays containing thousands of peptides with annotated phosphorylation/cleavage sites to study enzymatic activities and substrate specificities.
"JPT's unique peptide-based products strongly complement our existing portfolio of cell signaling reagents and services," states Rick Ryan, vice president of the drug discovery business unit for the bioscience division of Millipore.
"This will give Millipore customers access to patented high-throughput peptide synthesis and screening platforms, which accelerates research in the field of signal transduction".
Millipore offers a broad range of research products, including specialty reagents, kits, antibodies and molecular biology tools to a variety of research customers.
It specialises in tools for kinase research and is a leading providers of drug discovery services to pharmaceutical companies targeting kinase biology-based drugs.
The company also has ion-channel drug screening services to pharmaceutical companies.
Ion channel screening is an important tool for detecting potentially toxic side effects in therapeutic compounds.
"We applied our peptide synthesis and peptide array technologies to develop a series of tailor-made products and services to address the increasing demand in the field of kinase and protease research.
"We look forward to expanding the availability of these tools through Millipore's worldwide, dedicated sales channels," comments Holger Wenschuh, managing director at JPT.
